Letter to editor
Open Access
- 17 May 2022
- journal article
- Published by Scientific Scholar in International Journal of Molecular and Immuno Oncology
- Vol. 7, 58-60
- https://doi.org/10.25259/ijmio_10_2022
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Outcome in patients of hormone receptor (HR) positive (Her 2) negative metastatic breast cancer treated with palbociclib – A real-world experienceInternational Journal of Molecular and Immuno Oncology, 2022
- Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in IndiaSouth Asian Journal of Cancer, 2021
- Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese PerspectivesClinical Therapeutics, 2019
- Analytical validation of CanAssist-Breast: an immunohistochemistry based prognostic test for hormone receptor positive breast cancer patientsBMC Cancer, 2019
- Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysisEuropean Journal of Cancer, 2017
- Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)Breast Cancer Research and Treatment, 2016